CBD Source Comparison — Pharma vs Supplement
One molecule, two completely different products under the law.
- 1: FDA-approved CBD drugs (Epidiolex, since 2018)
- $$ Billions: Hemp CBD market size (est.) (largely unregulated)
- <0.3%: Legal THC ceiling (hemp) (dry-weight basis)
- None: FDA supplement rule finalized (still pending)
Pharmaceutical-grade CBD
Epidiolex went through rigorous trials before approval.
One product, full FDA drug review.
Hemp-derived CBD supplements
Legal under Farm Bill, but not FDA-approved as an ingredient.
Why the split confuses consumers
Same three letters, opposite evidence and quality standards.
Pharmaceutical Pathway — Epidiolex
Full FDA drug approval: trials, safety data, manufacturing standards.
- 3: Trial phases completed (plus preclinical work)
- 2018: FDA approval year (first plant-derived cannabinoid drug)
- Seizure disorders: Approved indication (rare epilepsy syndromes)
- cGMP: Manufacturing standard (current good manufacturing practice)
Preclinical & trial design
Years of animal and human trials precede any approval.
NDA review & approval
FDA reviews safety, efficacy, and manufacturing before sign-off.
Every batch is tested to a fixed standard.
Prescription-only dispensing
A doctor, not a shelf label, controls who gets it.
Supplement Pathway — Hemp CBD
Marketed without FDA premarket approval, in a tolerated gray zone.
- No: FDA premarket approval required (for hemp CBD supplements)
- <0.3%: THC limit for legal hemp (2018 Farm Bill threshold)
- Low: FDA enforcement priority (mostly warning letters)
- Voluntary: Independent lab testing (not federally mandated)
Farm Bill exemption
Legalized hemp, but not hemp-derived supplement ingredients.
No premarket FDA review
Products reach shelves without agency evaluation first.
"Not evaluated by the FDA" is the honest label.
Quality varies widely
Potency and purity depend entirely on the brand.
Jurisdictional Variation — Federal vs State
States and countries add their own layer atop federal rules.
- Many: States with added CBD rules (licensing, labeling, bans)
- Several: Countries w/ stricter limits (lower THC or Rx-only)
- THC <0.3%: Federal baseline (Farm Bill standard)
- Low: Consistency across jurisdictions (rules vary widely)
Federal floor, not ceiling
Federal law sets a minimum — states can go further.
Stricter state examples
Some states require licensing, testing, or outright bans.
Legal in one state, restricted in the next.
International divergence
Other countries classify CBD as medicine-only.
Jurisdiction snapshot (illustrative)
Consumer Outcome — One Label, Two Realities
Buyers face a confusing landscape hiding under one shared name.
- Rigorous trials: Evidence standard: pharma track (FDA-reviewed)
- Self-reported: Evidence standard: supplement track (not FDA-reviewed)
- Low: Consumer certainty (without reading labels closely)
- Pending rules: Path forward (FDA framework still incomplete)
Two products, one name
"CBD" can mean a tested drug or an untested supplement.
Quality gap in practice
Label accuracy and purity swing widely in the supplement market.
Ask which track a product actually followed.
What could resolve it
A finalized FDA supplement framework would narrow the gap.